{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:32:34Z","timestamp":1790839954085,"version":"4.1.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities of the heart muscle. It is classified into primary (genetic, mixed, or acquired) and secondary categories, resulting in various phenotypes including dilated, hypertrophic, and restrictive patterns. Hypertrophic cardiomyopathy, the most common primary form, can cause exertional dyspnea, presyncope, and sudden cardiac death. Dilated cardiomyopathy typically presents with heart failure symptoms, while restrictive cardiomyopathy is rarer and often associated with systemic diseases. Diagnosis involves a comprehensive evaluation including history, physical examination, electrocardiography, and echocardiography. Treatment options range from pharmacotherapy and lifestyle modifications to implantable cardioverter-defibrillators and heart transplantation in refractory cases.<\/jats:p>\n <\/jats:sec>\n \n Main body<\/jats:title>\n Anthracyclines, particularly doxorubicin, have emerged as crucial components in cancer treatment, demonstrating significant antitumor activity across various malignancies. These drugs have become standard in numerous chemotherapy regimens, improving patient outcomes. However, their use is associated with severe cardiotoxicity, including cardiomyopathy and heart failure. The mechanisms of anthracycline action and toxicity are complex, involving DNA damage, iron-mediated free radical production, and disruption of cardiovascular homeostasis. Doxorubicin-induced cardiomyopathy (DIC) is a severe complication of cancer treatment with a poor prognosis and limited effective treatments. The pathophysiology of DIC involves multiple mechanisms, including oxidative stress, inflammation, mitochondrial damage, and calcium homeostasis disorder. Despite extensive research, no effective treatment for established DIC is currently available. Dexrazoxane is the only FDA-approved protective agent, but it has limitations. Recent studies have explored various potential therapeutic approaches, including natural drugs, endogenous substances, new dosage forms, and herbal medicines. However, the lack of experimental models incorporating pre-existing cancer limits the understanding of DIC pathophysiology and treatment efficacy.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Cardiomyopathy, whether primary or secondary, poses a significant clinical challenge due to its varying etiologies and poor prognosis in advanced stages. Anthracycline-induced cardiomyopathy is a severe complication of chemotherapy, with doxorubicin being a notable contributor. Despite advancements in cancer therapies, the cardiotoxic effects of anthracyclines necessitate further investigation into effective preventive strategies and therapeutic interventions to improve patient outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s43044-025-00628-0","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:29:36Z","timestamp":1741624176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy"],"prefix":"10.1186","volume":"77","author":[{"given":"Sampat Singh","family":"Tanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheema","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"9","key":"628_CR1","first-page":"778","volume":"79","author":"R Wexler","year":"2009","unstructured":"Wexler R, Elton T, Pleister A, Feldman D (2009) Cardiomyopathy: an overview. Am Fam Phys 79(9):778","journal-title":"Am Fam Phys"},{"issue":"23","key":"628_CR2","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1161\/CIRCULATIONAHA.105.542894","volume":"112","author":"K Sliwa","year":"2005","unstructured":"Sliwa K, Damasceno A, Mayosi BM (2005) Epidemiology and etiology of cardiomyopathy in Africa. Circulation 112(23):3577\u20133583","journal-title":"Circulation"},{"issue":"2","key":"628_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heart.87.2.126","volume":"87","author":"K Miura","year":"2002","unstructured":"Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, Ohno Y, Tamakoshi A, Kawamura T, Inaba Y (2002) Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey. Heart 87(2):126\u2013130","journal-title":"Heart"},{"issue":"4","key":"628_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/jcm9040920","volume":"9","author":"S Lannou","year":"2020","unstructured":"Lannou S, Mansencal N, Couchoud C, Lassalle M, Dubourg O, Stengel B, Jacquelinet C, Charron P (2020) The public health burden of cardiomyopathies: insights from a nationwide inpatient study. J Clin Med 9(4):920","journal-title":"J Clin Med"},{"key":"628_CR5","first-page":"1","volume":"3","author":"A Albakri","year":"2019","unstructured":"Albakri A (2019) RASopathy-associated cardiomyopathy. Int. Med Care 3:1\u201313","journal-title":"Med Care"},{"issue":"10","key":"628_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.cardfail.2011.05.008","volume":"17","author":"A George","year":"2011","unstructured":"George A, Figueredo VM (2011) Alcoholic cardiomyopathy: a review. J Cardiac Fail 17(10):844\u2013849","journal-title":"J Cardiac Fail"},{"key":"628_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbadis.2014.06.030","volume":"2","author":"ZV Varga","year":"2015","unstructured":"Varga ZV, Giricz Z, Liaudet L, Hask\u00f3 G, Ferdinandy P, Pacher P (2015) Interplay of oxidative, nitrosative\/nitrative stress inflammation cell death and autophagy in diabetic cardiomyopathy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2:232\u2013242","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"issue":"1","key":"628_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15563650.2018.1497172","volume":"57","author":"P Hantson","year":"2019","unstructured":"Hantson P (2019) Mechanisms of toxic cardiomyopathy. Clin Toxicol 57(1):1\u20139","journal-title":"Clin Toxicol"},{"key":"628_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.54097\/hset.v6i.954","volume":"6","author":"C Huang","year":"2022","unstructured":"Huang C, Zhu S (2022) Doxorubicin-induced cardiomyopathy: mechanisms, diagnosis and therapeutic drugs. Highlights Sci Eng Technol 6:129\u2013135","journal-title":"Highlights Sci Eng Technol"},{"issue":"2","key":"628_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS (2010) Doxorubicin cardiomyopathy. Cardiology 115(2):155\u2013162","journal-title":"Cardiology"},{"key":"628_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (2017) Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 31:63\u201375","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"628_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.7326\/0003-4819-88-2-168","volume":"88","author":"MR Bristow","year":"1978","unstructured":"Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88(2):168\u2013175","journal-title":"Ann Intern Med"},{"issue":"7","key":"628_CR13","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","volume":"17","author":"EH Herman","year":"1999","unstructured":"Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu ZX, Ferrans VJ (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17(7):2237\u20132237","journal-title":"J Clin Oncol"},{"issue":"1","key":"628_CR14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41598-018-37862-3","volume":"9","author":"CS Abdullah","year":"2019","unstructured":"Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MA, Panchatcharam M, Pattillo CB, Orr AW, Sadoshima J, Hill JA, Bhuiyan MS (2019) Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep 9(1):2002","journal-title":"Sci Rep"},{"issue":"12","key":"628_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2459\/JCM.0b013e32833833a3","volume":"11","author":"A Iacovoni","year":"2010","unstructured":"Iacovoni A, De Maria R, Gavazzi A (2010) Alcoholic cardiomyopathy. J Cardiovasc Med 11(12):884\u2013892","journal-title":"J Cardiovasc Med"},{"key":"628_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.alcohol.2017.01.011","volume":"61","author":"J Rehm","year":"2017","unstructured":"Rehm J, Hasan OSM, Imtiaz S, Neufeld M (2017) Quantifying the contribution of alcohol to cardiomyopathy: a systematic review. Alcohol 61:9\u201315","journal-title":"Alcohol"},{"key":"628_CR17","unstructured":"Fern\u00e1ndez-Sol\u00e0 J, Riba RE (2017) J Alcohol Drug Depend"},{"issue":"4","key":"628_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00000441-200104000-00003","volume":"321","author":"MA Alpert","year":"2001","unstructured":"Alpert MA (2001) Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 321(4):225\u2013236","journal-title":"Am J Med Sci"},{"issue":"2","key":"628_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.amjms.2016.05.014","volume":"352","author":"S Bhatheja","year":"2016","unstructured":"Bhatheja S, Panchal HB, Ventura H, Paul TK (2016) Obesity cardiomyopathy: pathophysiologic factors and nosologic reevaluation. Am J Med Sci 352(2):219\u2013222","journal-title":"Am J Med Sci"},{"issue":"7","key":"628_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/antiox9070640","volume":"9","author":"A Ortega-Hern\u00e1ndez","year":"2020","unstructured":"Ortega-Hern\u00e1ndez A, Mart\u00ednez-Mart\u00ednez E, G\u00f3mez-Gordo R, L\u00f3pez-Andr\u00e9s N, Fern\u00e1ndez-Celis A, Guti\u00e9rrrez-Miranda B, Nieto ML, Alarc\u00f3n T, Alba C, G\u00f3mez-Garre D, Cachofeiro V (2020) The interaction between mitochondrial oxidative stress and gut microbiota in the cardiometabolic consequences in diet-induced obese rats. Antioxidants 9(7):640","journal-title":"Antioxidants"},{"issue":"4","key":"628_CR21","first-page":"1","volume":"2","author":"A Albakri","year":"2018","unstructured":"Albakri A (2018) Diabetic cardiomyopathy: a review of literature on clinical status and meta-analysis of tissue doppler diagnostic method and the clinical value of intensive glycemic control. Med Clin Arch 2(4):1\u201312","journal-title":"Med Clin Arch"},{"issue":"7","key":"628_CR22","first-page":"377","volume":"102","author":"J Lough","year":"1978","unstructured":"Lough J (1978) Cardiomyopathy produced by cigarette smoke. Ultrastructural observations in guinea pigs. Arch Pathol Lab Med 102(7):377\u2013380","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"628_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/cvr\/18.4.229","volume":"18","author":"A Gvozdjakova","year":"1984","unstructured":"Gvozdjakova A, Bada V, Sany L, Kucharska J, Krut\u00fd F, Bo\u017eek P, Tr\u0161tansk\u00fd L, Gvozdj\u00e1k J (1984) Smoke cardiomyopathy: disturbance of oxidative processes in myocardial mitochondria. Cardiovasc Res 18(4):229\u2013232","journal-title":"Cardiovasc Res"},{"issue":"2","key":"628_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/0003319707306300","volume":"59","author":"A Leone","year":"2008","unstructured":"Leone A, Balbarini A (2008) Exposure to passive smoking: a test to predict endothelial dysfunction and atherosclerotic lesions. Angiology 59(2):220\u2013223","journal-title":"Angiology"},{"issue":"3","key":"628_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1536\/ihj.37.401","volume":"37","author":"AJ Hartz","year":"1996","unstructured":"Hartz AJ, Ratner ER, Sinoway LI, Bartholomew MJ (1996) Smoking and idiopathic congestive cardiomyopathy. Jpn Heart J 37(3):401\u2013407","journal-title":"Jpn Heart J"},{"issue":"2","key":"628_CR26","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.15829\/1560-4071-2022-4789","volume":"27","author":"NG Poteshkina","year":"2022","unstructured":"Poteshkina NG, Krylova NS, Maslova MY, Kovalevskaya EA, Svanadze AM, Selivanova GB (2022) Hemodynamics at different levels of salt intake in patients with hypertrophic cardiomyopathy of different age groups. Rus J Cardiol 27(2):4789","journal-title":"Rus J Cardiol"},{"issue":"4","key":"628_CR27","first-page":"100","volume":"19","author":"OH \u0411epec\u043de\u0432a","year":"2015","unstructured":"\u0411epec\u043de\u0432a OH, \u041fapac\u0442ae\u0432a MM, \u0428\u0432e\u0434 HB, \u0418\u0432a\u043do\u0432a \u0413T, \u041ay\u0447ep A\u0413, \u041aa\u044e\u043ao\u0432 \u0418\u0413, C\u043c\u0438p\u043do\u0432 AB (2015) \u041ao\u043c\u0431\u0438\u043d\u0438po\u0432a\u043d\u043doe \u0432\u043b\u0438\u044f\u043d\u0438e \u0432o\u0437pac\u0442a \u0438 co\u043apa\u0449e\u043d\u0438\u044f \u043cacc\u044b \u0434e\u0439c\u0442\u0432y\u044e\u0449\u0438x \u043de\u0444po\u043do\u0432 \u043da pe\u043co\u0434e\u043b\u0438po\u0432a\u043d\u0438e \u043c\u0438o\u043aap\u0434a y \u043ap\u044bc. He\u0444po\u043bo\u0433\u0438\u044f 19(4):100\u2013107","journal-title":"He\u0444po\u043bo\u0433\u0438\u044f"},{"issue":"24","key":"628_CR28","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.3390\/ijms21249474","volume":"21","author":"Y Patel","year":"2020","unstructured":"Patel Y, Joseph J (2020) Sodium intake and heart failure. Int J Mol Sci 21(24):9474","journal-title":"Int J Mol Sci"},{"issue":"4","key":"628_CR29","first-page":"599","volume":"56","author":"A Cudnoch-Jedrzejewska","year":"2005","unstructured":"Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J (2005) Fluid consumption, electrolyte excretion. J Physiol Pharmacol 56(4):599\u2013610","journal-title":"J Physiol Pharmacol"},{"key":"628_CR30","doi-asserted-by":"crossref","unstructured":"Elkilany GN, Allah SB, Fedacko J, Singh J, Singh RB, Nanda NC, Salama M. (2019) Hypertensive cardiomyopathy: diagnostic approach and clinical differentiation from hypertrophic cardiomyopathy. J Cardiol Cardiovasc Ther, 15(4).","DOI":"10.19080\/JOCCT.2019.15.555919"},{"issue":"3","key":"628_CR31","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/0735-1097(89)90596-2","volume":"13","author":"R Karam","year":"1989","unstructured":"Karam R, Lever HM, Healy BP (1989) Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension?: a study of 78 patients. J Am Coll Cardiol 13(3):580\u2013584","journal-title":"J Am Coll Cardiol"},{"key":"628_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2741\/S375","volume":"5","author":"A Kostareva","year":"2013","unstructured":"Kostareva A, Sejersen T, Sjoberg G (2013) Genetic spectrum of cardiomyopathies with neuromuscular phenotype. Front Biosci (Schol Ed) 5:325\u2013340","journal-title":"Front Biosci (Schol Ed)"},{"issue":"4","key":"628_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000353805","volume":"126","author":"J Finsterer","year":"2013","unstructured":"Finsterer J, St\u00f6llberger C (2013) Ultrastructural findings in noncompaction prevail with neuromuscular disorders. Cardiology 126(4):219\u2013223","journal-title":"Cardiology"},{"issue":"1","key":"628_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2143\/AC.64.1.2034367","volume":"64","author":"J Finsterer","year":"2009","unstructured":"Finsterer J, Llberger CS (2009) Neuromuscular disorders associated with apical hypertrophic cardiomyopathy. Acta Cardiol 64(1):85\u201389","journal-title":"Acta Cardiol"},{"issue":"1","key":"628_CR35","first-page":"191","volume":"58","author":"Y Hayashi","year":"2000","unstructured":"Hayashi Y, Shimada K (2000) Secondary cardiomyopathy accompanied by neuromuscular disorders. Nihon rinsho. Japn J Clin Med 58(1):191\u2013195","journal-title":"Japn J Clin Med"},{"issue":"10","key":"628_CR36","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s11886-023-01944-0","volume":"25","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jia H, Song J (2023) Accurate classification of non-ischemic cardiomyopathy. Curr Cardiol Rep 25(10):1299\u20131317","journal-title":"Curr Cardiol Rep"},{"issue":"13","key":"628_CR37","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMcp030779","volume":"350","author":"RA Nishimura","year":"2004","unstructured":"Nishimura RA, Holmes DR Jr (2004) Hypertrophic obstructive cardiomyopathy. N Engl J Med 350(13):1320\u20131327","journal-title":"N Engl J Med"},{"key":"628_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2023.04.005","volume":"382","author":"D Massera","year":"2023","unstructured":"Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ (2023) How common is hypertrophic cardiomyopathy\u2026 really?: Disease prevalence revisited 27 years after CARDIA. Int J Cardiol 382:64\u201367","journal-title":"Int J Cardiol"},{"issue":"12","key":"628_CR39","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65(12):1249\u20131254","journal-title":"J Am Coll Cardiol"},{"key":"628_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijcard.2015.08.121","volume":"202","author":"VM Parato","year":"2016","unstructured":"Parato VM, Scarano M, Cicchitti V, Cannav\u00e0 G, Curr\u00f2 A (2016) Involvement of the right ventricle in hypertrophic cardiomyopathy and occurrence of right bundle branch block. Int J Cardiol 202:75\u201376","journal-title":"Int J Cardiol"},{"key":"628_CR41","unstructured":"Schultze-Berndt AK (2023) Patients with left ventricular noncompaction cardiomyopathy-comparison between pediatric and adult phenotypes (Doctoral dissertation)."},{"issue":"21","key":"628_CR42","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114(21):2232\u20132239","journal-title":"Circulation"},{"issue":"13","key":"628_CR43","first-page":"209","volume":"108","author":"C Prinz","year":"2011","unstructured":"Prinz C, Farr M, Hering D, Horstkotte D, Faber L (2011) The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int 108(13):209","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"628_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000175883","volume":"82","author":"M Tendera","year":"1993","unstructured":"Tendera M, Wycisk A, Schneeweiss A, Polo\u0144ski L, Wodniecki J (1993) Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology 82(5):335\u2013342","journal-title":"Cardiology"},{"key":"628_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s12265-013-9481-0","volume":"6","author":"X Lin","year":"2013","unstructured":"Lin X, Liang HY, Pinheiro A, Dimaano V, Sorensen L, Aon M, Tereshchenko LG, Chen Y, Xiang M, Abraham TP, Abraham MR (2013) Electromechanical relationship in hypertrophic cardiomyopathy. J Cardiovasc Transl Res 6:604\u2013615","journal-title":"J Cardiovasc Transl Res"},{"issue":"5","key":"628_CR46","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jelectrocard.2015.06.004","volume":"48","author":"E Pennacchini","year":"2015","unstructured":"Pennacchini E, Musumeci MB, Conte MR, St\u00f6llberger C, Formisano F, Bongioanni S, Francia P, Volpe M, Autore C (2015) Electrocardiographic evolution in patients with hypertrophic cardiomyopathy who develop a left ventricular apical aneurysm. J Electrocardiol 48(5):818\u2013825","journal-title":"J Electrocardiol"},{"key":"628_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pcad.2023.08.003","volume":"80","author":"N Mehra","year":"2023","unstructured":"Mehra N, Veselka J, Smedira N, Desai MY (2023) Invasive therapies for symptomatic obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis 80:46\u201355","journal-title":"Prog Cardiovasc Dis"},{"key":"628_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0410-8","volume":"9","author":"U Tayal","year":"2017","unstructured":"Tayal U, Prasad S, Cook SA (2017) Genetics and genomics of dilated cardiomyopathy and systolic heart failure. Genome Med 9:1\u201314","journal-title":"Genome Med"},{"key":"628_CR49","doi-asserted-by":"crossref","unstructured":"Wieczorek DF (2024) Dilated cardiomyopathy\u2013exploring the underlying causes. Med Res Arch, 12(12).","DOI":"10.18103\/mra.v12i12.6111"},{"key":"628_CR50","doi-asserted-by":"crossref","unstructured":"Towbin JA, Bowles NE (2006) Dilated cardiomyopathy: a tale of cytoskeletal proteins and beyond. J Cardiovasc Electrophysiol, 17(8).","DOI":"10.1111\/j.1540-8167.2006.00530.x"},{"issue":"5","key":"628_CR51","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ejhf.1461","volume":"21","author":"PM Seferovi\u0107","year":"2019","unstructured":"Seferovi\u0107 PM, Polovina M, Bauersachs J, Arad M, Ben Gal T, Lund LH, Felix SB, Arbustini E, Caforio AL, Farmakis D, Filippatos GS (2019) Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(5):553\u2013576","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"628_CR52","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1067\/mhj.2001.119137","volume":"142","author":"FA Ehlert","year":"2001","unstructured":"Ehlert FA, Cannom DS, Renfroe EG, Greene HL, Ledingham R, Mitchell LB, Anderson JL, Halperin BD, Herre JM, Luceri RM, Marinchak RA (2001) Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: Differences in presentation and outcome in the AVID registry. Am Heart J 142(5):816\u2013822","journal-title":"Am Heart J"},{"issue":"1","key":"628_CR53","doi-asserted-by":"publisher","DOI":"10.2174\/0102506882297515240320040938","volume":"5","author":"A Elsayed","year":"2024","unstructured":"Elsayed A, Kheirallah H, Alsuwayh A, Osman I (2024) Electrocardiographic patterns and ejection fraction in patients with nonischemic dilated cardiomyopathy: a cross-sectional retrospective study. New Emir Med J 5(1):e02506882297515","journal-title":"New Emir Med J"},{"issue":"1","key":"628_CR54","first-page":"41","volume":"18","author":"EK Massin","year":"1991","unstructured":"Massin EK (1991) Current treatment of dilated cardiomyopathy. Tex Heart Inst J 18(1):41","journal-title":"Tex Heart Inst J"},{"issue":"2","key":"628_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIR.0000000000001151","volume":"148","author":"C Bogle","year":"2023","unstructured":"Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, Feingold B, Lal AK, Lee TM, Canter CE, Lipshultz SE (2023) Treatment strategies for cardiomyopathy in children: a scientific statement from the American Heart Association. Circulation 148(2):174\u2013195","journal-title":"Circulation"},{"issue":"45","key":"628_CR56","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","volume":"43","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi C, Aimo A, Barison A, Emdin M, Porcari A, Linhart A, Keren A, Merlo M, Sinagra G (2022) Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J 43(45):4679\u20134693","journal-title":"Eur Heart J"},{"issue":"3","key":"628_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.31083\/j.rcm2303108","volume":"23","author":"M Chintanaphol","year":"2022","unstructured":"Chintanaphol M, Orgil BO, Alberson NR, Towbin JA, Purevjav E (2022) Restrictive cardiomyopathy: from genetics and clinical overview to animal modeling. Rev Cardiovasc Med 23(3):108","journal-title":"Rev Cardiovasc Med"},{"issue":"21","key":"628_CR58","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/01.CIR.101.21.2490","volume":"101","author":"NM Ammash","year":"2000","unstructured":"Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ (2000) Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101(21):2490\u20132496","journal-title":"Circulation"},{"issue":"1","key":"628_CR59","first-page":"2874902","volume":"2017","author":"A Rammos","year":"2017","unstructured":"Rammos A, Meladinis V, Vovas G, Patsouras D (2017) Restrictive cardiomyopathies: the importance of noninvasive cardiac imaging modalities in diagnosis and treatment\u2014a systematic review. Radiol Res Prac 2017(1):2874902","journal-title":"Radiol Res Prac"},{"issue":"4","key":"628_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.ihj.2015.05.012","volume":"67","author":"M Selvaganesh","year":"2015","unstructured":"Selvaganesh M, Arul AS, Balasubramanian S, Ganesan N, Mohammed SN, Sivakumar GS, Veeramani SR, Jeyasingh P, Sathishkumar S, Selvaraju S (2015) An unusual ECG pattern in restrictive cardiomyopathy. Indian Heart J 67(4):362\u2013367","journal-title":"Indian Heart J"},{"issue":"4","key":"628_CR61","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.athoracsur.2009.12.064","volume":"89","author":"H Zimmerman","year":"2010","unstructured":"Zimmerman H, Bose R, Smith R, Copeland JG (2010) Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 89(4):1211\u20131217","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"628_CR62","first-page":"1413","volume":"8","author":"P Santangeli","year":"2015","unstructured":"Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, Callans DJ, Lin D, Dixit S, Hutchinson MD, Riley MP (2015) Long-term outcome with catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy. Circ: Arrhythm Electrophysiol 8(6):1413\u20131421","journal-title":"Circ: Arrhythm Electrophysiol"},{"key":"628_CR63","doi-asserted-by":"crossref","unstructured":"Romero J, Mejia-Lopez E, Manrique C, Lucariello R (2013) Arrhythmogenic right ventricular cardiomyopathy (ARVC\/D): a systematic literature review. Clin Med Insights: Cardiol, 7, CMC-S10940.","DOI":"10.4137\/CMC.S10940"},{"key":"628_CR64","doi-asserted-by":"crossref","unstructured":"Iyer VR, Chin AJ. (2013) Arrhythmogenic right ventricular cardiomyopathy\/dysplasia (ARVC\/D). In: American Journal of Medical Genetics Part C: Seminars in Medical Genetics (Vol 163, No 3, pp 185\u2013197).","DOI":"10.1002\/ajmg.c.31368"},{"issue":"7","key":"628_CR65","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.hrthm.2009.03.013","volume":"6","author":"FI Marcus","year":"2009","unstructured":"Marcus FI, Zareba W, Calkins H, Towbin JA, Basso C, Bluemke DA, Estes NM III, Picard MH, Sanborn D, Thiene G, Wichter T (2009) Arrhythmogenic right ventricular cardiomyopathy\/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm 6(7):984\u2013992","journal-title":"Heart Rhythm"},{"issue":"7","key":"628_CR66","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.rec.2012.02.015","volume":"65","author":"G Quarta","year":"2012","unstructured":"Quarta G, Elliott PM (2012) Diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition) 65(7):599\u2013605","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"issue":"5","key":"628_CR67","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00045415-200109000-00005","volume":"9","author":"D Corrado","year":"2001","unstructured":"Corrado D, Basso C, Nava A, Thiene G (2001) Arrhythmogenic right ventricular cardiomyopathy: current diagnostic and management strategies. Cardiol Rev 9(5):259\u2013265","journal-title":"Cardiol Rev"},{"issue":"26","key":"628_CR68","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.2174\/138161210793176491","volume":"16","author":"F Migliore","year":"2010","unstructured":"Migliore F, Zorzi A, Silvano M, Rigato I, Basso C, Thiene G, Corrado D (2010) Clinical management of arrhythmogenic right ventricular cardiomyopathy: an update. Curr Pharm Des 16(26):2918\u20132928","journal-title":"Curr Pharm Des"},{"issue":"1","key":"628_CR69","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","volume":"21","author":"S Shi","year":"2023","unstructured":"Shi S, Chen Y, Luo Z, Nie G, Dai Y (2023) Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal 21(1):61","journal-title":"Cell Commun Signal"},{"key":"628_CR70","volume-title":"Organ directed toxicities of anticancer drugs","author":"JH Doroshow","year":"1988","unstructured":"Doroshow JH (1988) Role of reactive oxygen production in doxorubicin cardiac toxicity. Organ directed toxicities of anticancer drugs. Springer, MA"},{"issue":"1","key":"628_CR71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/med.21280","volume":"34","author":"FS Carvalho","year":"2014","unstructured":"Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1):106\u2013135","journal-title":"Med Res Rev"},{"issue":"16","key":"628_CR72","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1073\/pnas.95.16.9220","volume":"95","author":"J V\u00e1squez-Vivar","year":"1998","unstructured":"V\u00e1squez-Vivar J, Kalyanaraman B, Mart\u00e1sek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr (1998) Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci 95(16):9220\u20139225","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"628_CR73","doi-asserted-by":"publisher","first-page":"H1466","DOI":"10.1152\/ajpheart.00795.2008","volume":"296","author":"P Mukhopadhyay","year":"2009","unstructured":"Mukhopadhyay P, Rajesh M, B\u00e1tkai S, Kashiwaya Y, Hasko G, Liaudet L, Szab\u00f3 C, Pacher P (2009) Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol-Heart Circ Physiol 296(5):H1466\u2013H1483","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"4","key":"628_CR74","first-page":"371","volume":"38","author":"A Visnagri","year":"2023","unstructured":"Visnagri A, Oexner RR, Kmiotek-Wasylewska K, Zhang M, Zoccarato A, Shah AM (2023) Nicotinamide adenosine dinucleotide phosphate oxidase-mediated signaling in cardiac remodeling. Antioxid Redox Signal 38(4):371\u2013387","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"628_CR75","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/HYPERTENSIONAHA.109.142422","volume":"56","author":"SR Datla","year":"2010","unstructured":"Datla SR, Griendling KK (2010) Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 56(3):325\u2013330","journal-title":"Hypertension"},{"issue":"4","key":"628_CR76","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bbrc.2009.08.085","volume":"388","author":"M Gilleron","year":"2009","unstructured":"Gilleron M, Marechal X, Montaigne D, Franczak J, Neviere R, Lancel S (2009) NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis. Biochem Biophys Res Commun 388(4):727\u2013731","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"628_CR77","doi-asserted-by":"publisher","first-page":"6971","DOI":"10.1038\/s41598-024-57090-2","volume":"14","author":"Y Ma","year":"2024","unstructured":"Ma Y, Zhao HP, Yang LG, Li L, Wang AL, Zhang XJ, Wang K, Yang B, Zhu ZF, Zhang PJ, Wang JP (2024) NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy. Sci Rep 14(1):6971","journal-title":"Sci Rep"},{"issue":"22","key":"628_CR78","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, McLaughlin D, Robinson E, Harvey AP, Hookham MB, Shah AM, McDermott BJ, Grieve DJ (2010) Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Can Res 70(22):9287\u20139297","journal-title":"Can Res"},{"issue":"24","key":"628_CR79","first-page":"312","volume":"8","author":"R Li","year":"2019","unstructured":"Li R, Jia Z, Zhu H (2019) Regulation of Nrf2 signaling. React Oxygen Spec (Apex, NC) 8(24):312","journal-title":"React Oxygen Spec (Apex, NC)"},{"issue":"4","key":"628_CR80","first-page":"3333","volume":"16","author":"Z Guo","year":"2018","unstructured":"Guo Z, Yan M, Chen L, Fang P, Li Z, Wan Z, Cao S, Hou Z, Wei S, Li W, Zhang B (2018) Nrf2-dependent antioxidant response mediated the protective effect of tanshinone IIA on doxorubicin-induced cardiotoxicity. Exp Ther Med 16(4):3333\u20133344","journal-title":"Exp Ther Med"},{"issue":"1","key":"628_CR81","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41420-023-01565-0","volume":"9","author":"X Zhao","year":"2023","unstructured":"Zhao X, Tian Z, Sun M, Dong D (2023) Nrf2: a dark horse in doxorubicin-induced cardiotoxicity. Cell Death Discov 9(1):261","journal-title":"Cell Death Discov"},{"issue":"10","key":"628_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2022.183984","volume":"1864","author":"CA Fox","year":"2022","unstructured":"Fox CA, Romenskaia I, Dagda RK, Ryan RO (2022) Cardiolipin nanodisks confer protection against doxorubicin-induced mitochondrial dysfunction. Biochimica et Biophysica Acta (BBA)-Biomembranes 1864(10):183984","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"key":"628_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-015-0039-5","volume":"6","author":"M Moulin","year":"2015","unstructured":"Moulin M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R, Chaminade P (2015) Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biol Sex Differ 6:1\u201314","journal-title":"Biol Sex Differ"},{"key":"628_CR84","doi-asserted-by":"crossref","unstructured":"Sun D, Cui H, Rong L, Ma T, Li X, Ye Z, Li Z (2024) Sestrin2 protects human lens epithelial cells (HLECs) against apoptosis in cataracts formation: interaction between endoplasmic reticulum (ER) stress and oxidative stress (OS) is involved. Current Eye Res, 1\u201312.","DOI":"10.1080\/02713683.2024.2352058"},{"key":"628_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105383","volume":"164","author":"F Yarmohammadi","year":"2021","unstructured":"Yarmohammadi F, Rezaee R, Haye AW, Karimi G (2021) Endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity may be therapeutically targeted by natural and chemical compounds: a review. Pharmacol Res 164:105383","journal-title":"Pharmacol Res"},{"issue":"7","key":"628_CR86","volume":"1868","author":"AK Bagchi","year":"2021","unstructured":"Bagchi AK, Malik A, Akolkar G, Zimmer A, Bell\u00f3-Klein A, De Angelis K, Jassal DS, Fini MA, Stenmark KR, Singal PK (2021) Study of ER stress and apoptotic proteins in the heart and tumor exposed to doxorubicin. Mol Cell Res 1868(7):119039","journal-title":"Mol Cell Res"},{"key":"628_CR87","unstructured":"Malik A (2024) Doxorubicin-induced cardiomyopathy: role of endoplasmic reticulum stress."},{"key":"628_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","volume":"293","author":"M Pecoraro","year":"2016","unstructured":"Pecoraro M, Del Pizzo M, Marzocco S, Sorrentino R, Ciccarelli M, Iaccarino G, Pinto A, Popolo A (2016) Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol Appl Pharm 293:44\u201352","journal-title":"Toxicol Appl Pharm"},{"key":"628_CR89","doi-asserted-by":"crossref","unstructured":"Westermann D, Lettau O, Sobirey M, Riad A, Bader M, Schultheiss HP, Tsch\u00f6pe C. (2008) Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.","DOI":"10.1515\/BC.2008.070"},{"issue":"2","key":"628_CR90","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mmr.2013.1554","volume":"8","author":"RM Guo","year":"2013","unstructured":"Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Chen PX, Wu K, Zheng DD, Feng JQ (2013) Activation of the p38 MAPK\/NF-\u03baB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep 8(2):603\u2013608","journal-title":"Mol Med Rep"},{"issue":"5","key":"628_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23312","volume":"37","author":"HE Mohamed","year":"2023","unstructured":"Mohamed HE, Askar ME, Shaheen MA, Salama AE, Idris RA, Younis NN (2023) RETRACTED: Infliximab substantially re-silenced Wnt\/\u03b2-catenin signaling and ameliorated doxorubicin-induced cardiomyopathy in rats. J Biochem Mol Toxicol 37(5):e23312","journal-title":"J Biochem Mol Toxicol"},{"issue":"11","key":"628_CR92","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.3390\/molecules28114294","volume":"28","author":"N Sumneang","year":"2023","unstructured":"Sumneang N, Tanajak P, Oo TT (2023) Toll-like receptor 4 inflammatory perspective on doxorubicin-induced cardiotoxicity. Molecules 28(11):4294","journal-title":"Molecules"},{"issue":"3","key":"628_CR93","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1254\/fpj.20101","volume":"156","author":"M Umemura","year":"2021","unstructured":"Umemura M, Narikawa M, Tanaka R, Nemoto H, Nakakaji R, Nagasako A, Ishikawa Y (2021) Doxorubicin directly induced fibrotic change of cardiac fibroblasts. Nihon Yakurigaku zasshi Folia Pharmacologica Japonica 156(3):146\u2013151","journal-title":"Nihon Yakurigaku zasshi Folia Pharmacologica Japonica"},{"issue":"3","key":"628_CR94","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1536\/ihj.23-302","volume":"65","author":"Y Huyan","year":"2024","unstructured":"Huyan Y, Chen X, Chang Y, Hua X, Fan X, Shan D, Xu Z, Tao M, Zhang H, Liu S, Song J (2024) Single-cell transcriptomic analysis reveals myocardial fibrosis mechanism of doxorubicin-induced cardiotoxicity. Int Heart J 65(3):487\u2013497","journal-title":"Int Heart J"},{"issue":"7","key":"628_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022801","volume":"6","author":"T Feridooni","year":"2011","unstructured":"Feridooni T, Hotchkiss A, Remley-Carr S, Saga Y, Pasumarthi KB (2011) Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS ONE 6(7):e22801","journal-title":"PLoS ONE"},{"key":"628_CR96","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.omtn.2017.07.004","volume":"8","author":"H Qi","year":"2017","unstructured":"Qi H, Liu Y, Li S, Chen Y, Li L, Cao Y, Mingyao E, Shi P, Song C, Li B, Sun H (2017) Activation of AMPK attenuated cardiac fibrosis by inhibiting CDK2 via p21\/p27 and miR-29 family pathways in rats. Mol Ther-Nucleic Acids 8:277\u2013290","journal-title":"Mol Ther-Nucleic Acids"},{"key":"628_CR97","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.yjmcc.2016.01.001","volume":"91","author":"EP Daskalopoulos","year":"2016","unstructured":"Daskalopoulos EP, Dufeys C, Bertrand L, Beauloye C, Horman S (2016) AMPK in cardiac fibrosis and repair: actions beyond metabolic regulation. J Mol Cell Cardiol 91:188\u2013200","journal-title":"J Mol Cell Cardiol"},{"key":"628_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-021-00394-z","volume":"12","author":"L Grimbert","year":"2021","unstructured":"Grimbert L, Sanz MN, Gressette M, Rucker-Martin C, Novotova M, Solgadi A, Karoui A, Gomez S, Bedouet K, Jacquet E, Lemaire C (2021) Spatiotemporal AMPK\u03b12 deletion in mice induces cardiac dysfunction, fibrosis and cardiolipin remodeling associated with mitochondrial dysfunction in males only. Biol Sex Differ 12:1\u201324","journal-title":"Biol Sex Differ"},{"key":"628_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.839644","volume":"9","author":"M Singh","year":"2022","unstructured":"Singh M, Nicol AT, DelPozzo J, Wei J, Singh M, Nguyen T, Kobayashi S, Liang Q (2022) Demystifying the relationship between metformin, AMPK, and doxorubicin cardiotoxicity. Front Cardiovasc Med 9:839644","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"628_CR100","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm KN, Tyler DJ (2020) The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovasc Drugs Ther 34(2):255\u2013269","journal-title":"Cardiovasc Drugs Ther"},{"key":"628_CR101","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.freeradbiomed.2015.07.016","volume":"89","author":"JS Koh","year":"2015","unstructured":"Koh JS, Yi CO, Ahn JW, Park JR, Lee JE, Kim JH, Hwang JY, Roh GS (2015) Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. Free Radical Biol Med 89:54\u201361","journal-title":"Free Radical Biol Med"},{"issue":"11","key":"628_CR102","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/ph13110348","volume":"13","author":"MA Saleh","year":"2020","unstructured":"Saleh MA, Antar SA, Hazem RM, El-Azab MF (2020) Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in Ehrlich ascites carcinoma bearing mice: Modulation of monocyte chemoattractant protein-1 and Jun N-terminal kinase-1 pathways. Pharmaceuticals 13(11):348","journal-title":"Pharmaceuticals"},{"issue":"2","key":"628_CR103","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/hon.811","volume":"25","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF, Focosi D (2007) Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. Hematol Oncol 25(2):96\u201397","journal-title":"Hematol Oncol"},{"issue":"9","key":"628_CR104","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3390\/antiox12091720","volume":"12","author":"Shipra","year":"2023","unstructured":"Shipra, Tembhre MK, Hote MP, Bhari N, Lakshmy R, Kumaran SS (2023) PGC-1\u03b1 agonist rescues doxorubicin-induced cardiomyopathy by mitigating the oxidative stress and necroptosis. Antioxidants 12(9):1720","journal-title":"Antioxidants"},{"issue":"6","key":"628_CR105","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1042\/EBC20170022","volume":"61","author":"J Mialet-Perez","year":"2017","unstructured":"Mialet-Perez J, Vindis C (2017) Autophagy in health and disease: focus on the cardiovascular system. Essays Biochem 61(6):721\u2013732","journal-title":"Essays Biochem"},{"key":"628_CR106","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/bs.pmbts.2020.04.022","volume":"172","author":"M Abdellatif","year":"2020","unstructured":"Abdellatif M, Ljubojevic-Holzer S, Madeo F, Sedej S (2020) Autophagy in cardiovascular health and disease. Prog Mol Biol Transl Sci 172:87\u2013106","journal-title":"Prog Mol Biol Transl Sci"},{"key":"628_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2017.01.007","volume":"104","author":"JJ Bartlett","year":"2017","unstructured":"Bartlett JJ, Trivedi PC, Pulinilkunnil T (2017) Autophagic dysregulation in doxorubicin cardiomyopathy. J Mol Cell Cardiol 104:1\u20138","journal-title":"J Mol Cell Cardiol"},{"issue":"24","key":"628_CR108","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.lfs.2013.10.013","volume":"93","author":"AJ Dirks-Naylor","year":"2013","unstructured":"Dirks-Naylor AJ (2013) The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci 93(24):913\u2013916","journal-title":"Life Sci"},{"key":"628_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116210","volume":"453","author":"P Kawalec","year":"2022","unstructured":"Kawalec P, Martens MD, Field JT, Mughal W, Caymo AM, Chapman D, Xiang B, Ghavami S, Dolinsky VW, Gordon JW (2022) Differential impact of doxorubicin dose on cell death and autophagy pathways during acute cardiotoxicity. Toxicol Appl Pharmacol 453:116210","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"628_CR110","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3892\/mmr.2014.2055","volume":"9","author":"D Zhao","year":"2014","unstructured":"Zhao D, Yuan H, Yi F, Meng C, Zhu Q (2014) Autophagy prevents doxorubicin-induced apoptosis in osteosarcoma. Mol Med Rep 9(5):1975\u20131981","journal-title":"Mol Med Rep"},{"issue":"1","key":"628_CR111","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bcp.2012.10.005","volume":"85","author":"BJ Sishi","year":"2013","unstructured":"Sishi BJ, Loos B, van Rooyen J, Engelbrecht AM (2013) Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 85(1):124\u2013134","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"628_CR112","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132\u2013141","journal-title":"Nat Cell Biol"},{"issue":"7","key":"628_CR113","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/auto.7.7.15451","volume":"7","author":"AS L\u00f6ffler","year":"2011","unstructured":"L\u00f6ffler AS, Alers S, Dieterle AM, Keppeler H, Franz-Wachtel M, Kundu M, Campbell DG, Wesselborg S, Alessi DR, Stork B (2011) Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. Autophagy 7(7):696\u2013706","journal-title":"Autophagy"},{"key":"628_CR114","doi-asserted-by":"crossref","unstructured":"Li Y, Chen Y (2019) AMPK and autophagy, Autophagy Biol Dis Basic Sci, 85\u2013108.","DOI":"10.1007\/978-981-15-0602-4_4"},{"issue":"1","key":"628_CR115","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1074\/jbc.M109.070037","volume":"285","author":"S Kobayashi","year":"2010","unstructured":"Kobayashi S, Volden P, Timm D, Mao K, Xu X, Liang Q (2010) Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. J Biol Chem 285(1):793\u2013804","journal-title":"J Biol Chem"},{"issue":"16","key":"628_CR116","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJM199704173361603","volume":"336","author":"G Olivetti","year":"1997","unstructured":"Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC (1997) Apoptosis in the failing human heart. N Engl J Med 336(16):1131\u20131141","journal-title":"N Engl J Med"},{"issue":"7","key":"628_CR117","first-page":"1789","volume":"60","author":"OJ Arola","year":"2000","unstructured":"Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, Voipio-Pulkki LM (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Can Res 60(7):1789\u20131792","journal-title":"Can Res"},{"key":"628_CR118","doi-asserted-by":"publisher","first-page":"43","DOI":"10.12688\/f1000research.10568.1","volume":"6","author":"HM Tang","year":"2017","unstructured":"Tang HM, Talbot CC Jr, Fung MC, Tang HL (2017) Molecular signature of anastasis for reversal of apoptosis. F1000Research 6:43","journal-title":"F1000Research"},{"issue":"3","key":"628_CR119","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00109-016-1494-0","volume":"95","author":"C Kankeu","year":"2017","unstructured":"Kankeu C, Clarke K, Passante E, Huber HJ (2017) Doxorubicin-induced chronic dilated cardiomyopathy\u2014the apoptosis hypothesis revisited. J Mol Med 95(3):239\u2013248","journal-title":"J Mol Med"},{"issue":"3","key":"628_CR120","doi-asserted-by":"publisher","first-page":"556","DOI":"10.7150\/ijbs.29907","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhu JX, Ma ZG, Wu HM, Xu SC, Song P, Kong CY, Yuan YP, Deng W, Tang QZ (2019) Rosmarinic acid alleviates cardiomyocyte apoptosis via cardiac fibroblast in doxorubicin-induced cardiotoxicity. Int J Biol Sci 15(3):556","journal-title":"Int J Biol Sci"},{"issue":"2","key":"628_CR121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cvr\/cvq335","volume":"89","author":"M Konishi","year":"2011","unstructured":"Konishi M, Haraguchi G, Ohigashi H, Ishihara T, Saito K, Nakano Y, Isobe M (2011) Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation. Cardiovasc Res 89(2):309\u2013319","journal-title":"Cardiovasc Res"},{"key":"628_CR122","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2119\/molmed.2014.00261","volume":"21","author":"E Hao","year":"2015","unstructured":"Hao E, Mukhopadhyay P, Cao Z, Erd\u00e9lyi K, Holovac E, Liaudet L, Lee WS, Hask\u00f3 G, Mechoulam R, Pacher P (2015) Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol Med 21:38\u201345","journal-title":"Mol Med"},{"issue":"5","key":"628_CR123","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","volume":"71","author":"PF Cosper","year":"2011","unstructured":"Cosper PF, Leinwand LA (2011) Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Can Res 71(5):1710\u20131720","journal-title":"Can Res"},{"key":"628_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.812578","volume":"9","author":"DS Chen","year":"2022","unstructured":"Chen DS, Yan J, Yang PZ (2022) Cardiomyocyte atrophy, an underestimated contributor in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med 9:812578","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"628_CR125","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1006\/jmcc.1996.0350","volume":"29","author":"K Rakusan","year":"1997","unstructured":"Rakusan K, Heron MI, Kolar F, Korecky B (1997) Transplantation-induced atrophy of normal and hypertrophic rat hearts: effect on cardiac myocytes and capillaries. J Mol Cell Cardiol 29(3):1045\u20131054","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"628_CR126","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/cvr\/cvn076","volume":"79","author":"Y Yamamoto","year":"2008","unstructured":"Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, Azuma J (2008) Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79(1):89\u201396","journal-title":"Cardiovasc Res"},{"key":"628_CR127","doi-asserted-by":"crossref","unstructured":"Murugan AK (2019) mTOR: role in cancer, metastasis and drug resistance. In: Seminars in cancer biology (Vol. 59, pp. 92\u2013111). Academic Press.","DOI":"10.1016\/j.semcancer.2019.07.003"},{"issue":"3","key":"628_CR128","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005234","volume":"12","author":"MS Willis","year":"2019","unstructured":"Willis MS, Parry TL, Brown DI, Mota RI, Huang W, Beak JY, Sola M, Zhou C, Hicks ST, Caughey MC, D\u2019Agostino RB Jr (2019) Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle\u2014specific ubiquitin ligase MuRF1. Circ Heart Fail 12(3):e005234","journal-title":"Circ Heart Fail"},{"issue":"3","key":"628_CR129","first-page":"101","volume":"17","author":"MG da Silva","year":"2012","unstructured":"da Silva MG, Mattos E, Camacho-Pereira J, Domitrovic T, Galina A, Costa MW, Kurtenbach E (2012) Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases. Exp Clin Cardiol 17(3):101","journal-title":"Exp Clin Cardiol"},{"issue":"3","key":"628_CR130","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1152\/japplphysiol.00210.2014","volume":"117","author":"AN Kavazis","year":"2014","unstructured":"Kavazis AN, Smuder AJ, Powers SK (2014) Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle. J Appl Physiol 117(3):223\u2013230","journal-title":"J Appl Physiol"},{"issue":"13","key":"628_CR131","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","volume":"295","author":"P Xia","year":"2020","unstructured":"Xia P, Chen J, Liu Y, Fletcher M, Jensen BC, Cheng Z (2020) Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2\u2013mediated activation of forkhead box O1. J Biol Chem 295(13):4265\u20134276","journal-title":"J Biol Chem"},{"issue":"3","key":"628_CR132","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3177\/jnsv.64.229","volume":"64","author":"Y Hirose","year":"2018","unstructured":"Hirose Y, Onishi T, Miura S, Hatazawa Y, Kamei Y (2018) Vitamin D attenuates FOXO1-target atrophy gene expression in C2C12 muscle cells. J Nutr Sci Vitaminol 64(3):229\u2013232","journal-title":"J Nutr Sci Vitaminol"},{"issue":"11","key":"628_CR133","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1073\/pnas.1119338109","volume":"109","author":"Y Ichikawa","year":"2012","unstructured":"Ichikawa Y, Bayeva M, Ghanefar M, Potini V, Sun L, Mutharasan RK, Wu R, Khechaduri A, Jairaj Naik T, Ardehali H (2012) Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export. Proc Natl Acad Sci 109(11):4152\u20134157","journal-title":"Proc Natl Acad Sci"},{"issue":"32","key":"628_CR134","doi-asserted-by":"publisher","first-page":"11002","DOI":"10.1074\/jbc.RA120.013229","volume":"295","author":"A Seguin","year":"2020","unstructured":"Seguin A, Jia X, Earl AM, Li L, Wallace J, Qiu A, Bradley T, Shrestha R, Troadec MB, Hockin M, Titen S (2020) The mitochondrial metal transporters mitoferrin1 and mitoferrin2 are required for liver regeneration and cell proliferation in mice. J Biol Chem 295(32):11002\u201311020","journal-title":"J Biol Chem"},{"key":"628_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"B Kalyanaraman","year":"2020","unstructured":"Kalyanaraman B (2020) Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol 29:101394","journal-title":"Redox Biol"},{"issue":"15","key":"628_CR136","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93358","volume":"2","author":"T Shimauchi","year":"2017","unstructured":"Shimauchi T, Numaga-Tomita T, Ito T, Nishimura A, Matsukane R, Oda S, Hoka S, Ide T, Koitabashi N, Uchida K, Sumimoto H (2017) TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight 2(15):e93358","journal-title":"JCI Insight"},{"issue":"12","key":"628_CR137","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cjco.2022.08.006","volume":"4","author":"K Dadson","year":"2022","unstructured":"Dadson K, Thavendiranathan P, Hauck L, Grothe D, Azam MA, Stanley-Hasnain S, Mahiny-Shahmohammady D, Si D, Bokhari M, Lai PF, Mass\u00e9 S (2022) Statins protect against early stages of doxorubicin-induced cardiotoxicity through the regulation of Akt signaling and SERCA2. CJC Open 4(12):1043\u20131052","journal-title":"CJC Open"},{"issue":"12","key":"628_CR138","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10552-021-01487-1","volume":"32","author":"M Obasi","year":"2021","unstructured":"Obasi M, Abovich A, Vo JB, Gao Y, Papatheodorou SI, Nohria A, Asnani A, Partridge AH (2021) Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and\/or trastuzumab: a systematic review and meta-analysis. Cancer Causes Control 32(12):1395\u20131405","journal-title":"Cancer Causes Control"},{"key":"628_CR139","unstructured":"Fluvastatin pretreatment attenuated doxorubicin-induced cardiotoxicity in mice by reducing oxidative stress, inflammation, and apoptosis while enhancing antioxidative mechanisms"},{"key":"628_CR140","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.phrs.2014.11.003","volume":"91","author":"C Henninger","year":"2015","unstructured":"Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, Fritz G (2015) Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacol Res 91:47\u201356","journal-title":"Pharmacol Res"},{"issue":"1","key":"628_CR141","doi-asserted-by":"publisher","first-page":"9850","DOI":"10.1038\/s41598-019-46367-6","volume":"9","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, Matsushima S, Okabe K, Ikeda M, Ishikita A, Tadokoro T, Enzan N, Yamamoto T, Sada M, Deguchi H, Morimoto S (2019) Blockade of L-type Ca2+ channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-\u03baB pathway. Sci Rep 9(1):9850","journal-title":"Sci Rep"},{"issue":"9","key":"628_CR142","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/life11090880","volume":"11","author":"A Abdelatty","year":"2021","unstructured":"Abdelatty A, Ahmed MS, Abdel-Kareem MA, Dmerdash M, Mady R, Saad AS, Albrakati A, Elmahallawy EK, Elsawak A, Abdo W (2021) Acute and delayed doxorubicin-induced myocardiotoxicity associated with elevation of cardiac biomarkers, depletion of cellular antioxidant enzymes, and several histopathological and ultrastructural changes. Life 11(9):880","journal-title":"Life"},{"issue":"2","key":"628_CR143","first-page":"31","volume":"2","author":"HM Alkuraishy","year":"2017","unstructured":"Alkuraishy HM, Al-Gareeb AI, Al-Hussaniy HA (2017) Doxorubicin-induced cardiotoxicity: molecular mechanism and protection by conventional drugs and natural products. Int J Clin Oncol Cancer Res 2(2):31\u201344","journal-title":"Int J Clin Oncol Cancer Res"},{"key":"628_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-019-0912-0","volume":"19","author":"HS Al-Malky","year":"2019","unstructured":"Al-Malky HS, Osman AMM, Damanhouri ZA, Alkreathy HM, Al Aama JY, Ramadan WS, Al Mahdi HB (2019) Modulation of doxorubicin-induced expression of the multidrug resistance gene in breast cancer cells by diltiazem and protection against cardiotoxicity in experimental animals. Cancer Cell Int 19:1\u201310","journal-title":"Cancer Cell Int"},{"issue":"1","key":"628_CR145","doi-asserted-by":"publisher","first-page":"1521020","DOI":"10.1155\/2017\/1521020","volume":"2017","author":"D Cappetta","year":"2017","unstructured":"Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S, Urbanek K (2017) Oxidative stress and cellular response to doxorubicin: a common factor in the complex milieu of anthracycline cardiotoxicity. Oxid Med Cell Longev 2017(1):1521020","journal-title":"Oxid Med Cell Longev"},{"key":"628_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2022.104818","volume":"127","author":"T Chunchai","year":"2022","unstructured":"Chunchai T, Arinno A, Ongnok B, Pantiya P, Khuanjing T, Prathumsap N, Maneechote C, Chattipakorn N, Chattipakorn SC (2022) Ranolazine alleviated cardiac\/brain dysfunction in doxorubicin-treated rats. Exp Mol Pathol 127:104818","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"628_CR147","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1517\/14740338.2014.845167","volume":"13","author":"A Avallone","year":"2014","unstructured":"Avallone A, Gennaro ED, Silvestro L, Iaffaioli VR, Budillon A (2014) Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf 13(1):113\u2013129","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"628_CR148","first-page":"304","volume":"32","author":"A Sikandar","year":"2020","unstructured":"Sikandar A, Farhat K, Afzal A, Ajmal K, Laeeq M, Khokhar A (2020) Protective effects of trimetazidine against doxorubicin-induced cardiotoxicity and hepatotoxicity in mice. J Ayub Med Coll Abbottabad 32(3):304\u2013309","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"2","key":"628_CR149","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0973-1482.136557","volume":"10","author":"I Salouege","year":"2014","unstructured":"Salouege I, Ali RB, Sa\u00efd DB, Elkadri N, Kourda N, Lakhal M, Klouz A (2014) Means of evaluation and protection from doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. J Cancer Res Ther 10(2):274\u2013278","journal-title":"J Cancer Res Ther"},{"key":"628_CR150","doi-asserted-by":"crossref","unstructured":"Avagimyan A, Pogosova N, Kakturskiy L, Sheibani M, Challa A, Kogan E, Fogacci F, Mikhaleva L, Vandysheva R, Yakubovskaya M, Faggiano A (2024) Doxorubicin-related cardiotoxicity: Review of fundamental pathways of cardiovascular system injury.\u00a0Cardiovasc Pathol, 107683.","DOI":"10.1016\/j.carpath.2024.107683"},{"issue":"17","key":"628_CR151","doi-asserted-by":"publisher","first-page":"10146","DOI":"10.3390\/ijms231710146","volume":"23","author":"PL Hsieh","year":"2022","unstructured":"Hsieh PL, Chu PM, Cheng HC, Huang YT, Chou WC, Tsai KL, Chan SH (2022) Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating AKT-mediated oxidative stress, cardiac remodeling, and inflammation. Int J Mol Sci 23(17):10146","journal-title":"Int J Mol Sci"},{"issue":"6","key":"628_CR152","doi-asserted-by":"publisher","first-page":"339","DOI":"10.14744\/AnatolJCardiol.2023.2825","volume":"27","author":"S Ulusan","year":"2023","unstructured":"Ulusan S, G\u00fclle K, Peynirci A, Sevimli M, Karaibrahimo\u011flu A (2023) Dapagliflozin may protect against doxorubicin-induced cardiotoxicity. Anatol J Cardiol 27(6):339","journal-title":"Anatol J Cardiol"},{"issue":"7","key":"628_CR153","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00204-022-03298-y","volume":"96","author":"WT Chang","year":"2022","unstructured":"Chang WT, Shih JY, Lin YW, Chen ZC, Kan WC, Lin TH, Hong CS (2022) Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3. Arch Toxicol 96(7):2021\u20132032","journal-title":"Arch Toxicol"},{"issue":"5","key":"628_CR154","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.hrtlng.2017.06.003","volume":"46","author":"N Miaris","year":"2017","unstructured":"Miaris N, Zezas S, Sgouros J, Zirou DC, Gkoura S, Stamoulis G, Angelopoulou H, Avgeropoulos G, Samantas E (2017) Effective use of levosimendan in anthracycline-induced cardiomyopathy: a case report. Heart Lung 46(5):382\u2013386","journal-title":"Heart Lung"},{"issue":"3","key":"628_CR155","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/cvr\/cvz163","volume":"116","author":"P Efentakis","year":"2020","unstructured":"Efentakis P, Varela A, Chavdoula E, Sigala F, Sanoudou D, Tenta R, Gioti K, Kostomitsopoulos N, Papapetropoulos A, Tasouli A, Farmakis D (2020) Levosimendan prevents doxorubicin-induced cardiotoxicity in time-and dose-dependent manner: implications for inotropy. Cardiovasc Res 116(3):576\u2013591","journal-title":"Cardiovasc Res"},{"issue":"1","key":"628_CR156","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12871-022-01663-z","volume":"22","author":"ZS Li","year":"2022","unstructured":"Li ZS, Wang K, Pan T, Sun YH, Liu C, Cheng YQ, Zhang H, Zhang HT, Wang DJ, Chen ZJ (2022) The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis. BMC Anesthesiol 22(1):135","journal-title":"BMC Anesthesiol"},{"issue":"1","key":"628_CR157","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","volume":"134","author":"A Tashakori Beheshti","year":"2016","unstructured":"Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G, Zarifian A, Homaei Shandiz F, Fazlinezhad A (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134(1):47\u201353","journal-title":"Cardiology"},{"issue":"2","key":"628_CR158","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/stem.1868","volume":"33","author":"WC Chen","year":"2015","unstructured":"Chen WC, Baily JE, Corselli M, D\u00edaz ME, Sun B, Xiang G, Gray GA, Huard J, P\u00e9ault B (2015) Human myocardial pericytes: multipotent mesodermal precursors exhibiting cardiac specificity. Stem Cells 33(2):557\u2013573","journal-title":"Stem Cells"},{"issue":"5","key":"628_CR159","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","volume":"144","author":"R Jhorawat","year":"2016","unstructured":"Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, Malhotra P, Jain S (2016) Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res 144(5):725\u2013729","journal-title":"Indian J Med Res"},{"issue":"6","key":"628_CR160","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/15376516.2012.666658","volume":"22","author":"MA Ibrahim","year":"2012","unstructured":"Ibrahim MA, Morsy MA, Hafez HM, Gomaa WM, Abdelrahman AM (2012) Effect of selective and non-selective cyclooxygenase inhibitors on doxorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicol Mech Methods 22(6):424\u2013431","journal-title":"Toxicol Mech Methods"},{"issue":"2","key":"628_CR161","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","volume":"142","author":"A Hiona","year":"2011","unstructured":"Hiona A, Lee AS, Nagendran J, Xie X, Connolly AJ, Robbins RC, Wu JC (2011) Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg 142(2):396\u2013403","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"628_CR162","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","volume":"185","author":"DL Santos","year":"2002","unstructured":"Santos DL, Moreno AJM, Leino RL, Froberg MK, Wallace KB (2002) Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 185(3):218\u2013227","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"628_CR163","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cvr\/cvx162","volume":"114","author":"R Hullin","year":"2018","unstructured":"Hullin R, M\u00e9trich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D (2018) Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovasc Res 114(2):272\u2013281","journal-title":"Cardiovasc Res"},{"issue":"23","key":"628_CR164","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, Gelber RD, Colan SD (2002) Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20(23):4517\u20134522","journal-title":"J Clin Oncol"},{"issue":"2","key":"628_CR165","doi-asserted-by":"publisher","DOI":"10.1111\/jfd.13890","volume":"47","author":"F Zhan","year":"2024","unstructured":"Zhan F, Zhou S, Shi F, Li Q, Lin L, Qin Z (2024) Identifying the function of the PI3K-AKT pathway during the pathogenic infection of Macrobrachium rosenbergii. J Fish Dis 47(2):e13890","journal-title":"J Fish Dis"},{"issue":"7","key":"628_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040763","volume":"7","author":"Y Ma","year":"2012","unstructured":"Ma Y, Zhang X, Bao H, Mi S, Cai W, Yan H, Wang Q, Wang Z, Yan J, Fan G, Lindsey ML (2012) Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS ONE 7(7):e40763","journal-title":"PLoS ONE"},{"issue":"11","key":"628_CR167","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5152\/AnatolJCardiol.2021.356","volume":"25","author":"F Dinda\u015f","year":"2021","unstructured":"Dinda\u015f F, G\u00fcng\u00f6r H, Ekici M, Akokay P, Erhan F, Do\u011fdu\u015f M, Y\u0131lmaz MB (2021) Angiotensin receptor-neprilysin inhibition by sacubitril\/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and caspase 3 apoptotic pathway. Anatol J Cardiol 25(11):821","journal-title":"Anatol J Cardiol"},{"issue":"10","key":"628_CR168","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1016\/j.ymthe.2024.08.030","volume":"32","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zou Y, Qiao L, Lin L (2024) Integrative proteomic and metabolomic elucidation of cardiomyopathy with in vivo and in vitro models and clinical samples. Mol Ther 32(10):3288\u20133312","journal-title":"Mol Ther"},{"issue":"7","key":"628_CR169","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms23073587","volume":"23","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, Matsuo N, Ichikawa K, Iwasaki K, Naito T, Namba Y (2022) Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus. Int J Mol Sci 23(7):3587","journal-title":"Int J Mol Sci"},{"issue":"5","key":"628_CR170","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/1078155218783238","volume":"25","author":"CE Sheppard","year":"2019","unstructured":"Sheppard CE, Anwar M (2019) The use of sacubitril\/valsartan in anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract 25(5):1231\u20131234","journal-title":"J Oncol Pharm Pract"},{"key":"628_CR171","doi-asserted-by":"publisher","first-page":"9977","DOI":"10.1007\/s11042-019-07742-7","volume":"79","author":"M Abdel-Basset","year":"2020","unstructured":"Abdel-Basset M, Gamal A, Manogaran G, Son LH, Long HV (2020) A novel group decision making model based on neutrosophic sets for heart disease diagnosis. Multim Tools Appl 79:9977\u201310002","journal-title":"Multim Tools Appl"},{"issue":"1","key":"628_CR172","first-page":"9583268","volume":"2016","author":"P Xia","year":"2016","unstructured":"Xia P, Liu Y, Cheng Z (2016) Signaling pathways in cardiac myocyte apoptosis. Biomed Res Int 2016(1):9583268","journal-title":"Biomed Res Int"},{"issue":"1","key":"628_CR173","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.196","volume":"17","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17(1):81\u201389","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"628_CR174","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1148\/radiol.2021210914","volume":"302","author":"J Liu","year":"2022","unstructured":"Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L, Song J, Zhu Y, Kang L, Wang J, Song L (2022) Patterns of replacement fibrosis in hypertrophic cardiomyopathy. Radiology 302(2):298\u2013306","journal-title":"Radiology"},{"key":"628_CR175","unstructured":"Imondi AR (1998) Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects. In: Seminars in oncology\u00a0(Vol. 25, No. 4 Suppl 10, pp. 22\u201330)."},{"issue":"6","key":"628_CR176","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.bjp.0707294","volume":"151","author":"D Lebrecht","year":"2007","unstructured":"Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA (2007) Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151(6):771\u2013778","journal-title":"Br J Pharmacol"},{"issue":"9","key":"628_CR177","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/106002809402800912","volume":"28","author":"CF Seifert","year":"1994","unstructured":"Seifert CF, Nesser ME, Thompson DF (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28(9):1063\u20131072","journal-title":"Ann Pharmacother"},{"issue":"1","key":"628_CR178","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10020-023-00686-7","volume":"29","author":"T Khuanjing","year":"2023","unstructured":"Khuanjing T, Maneechote C, Ongnok B, Prathumsap N, Arinno A, Chunchai T, Arunsak B, Chattipakorn SC, Chattipakorn N (2023) Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways. Mol Med 29(1):123","journal-title":"Mol Med"},{"issue":"3","key":"628_CR179","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13311-021-01092-9","volume":"18","author":"B Ongnok","year":"2021","unstructured":"Ongnok B, Khuanjing T, Chunchai T, Pantiya P, Kerdphoo S, Arunsak B, Nawara W, Jaiwongkam T, Apaijai N, Chattipakorn N, Chattipakorn SC (2021) Donepezil protects against doxorubicin-induced chemobrain in rats via attenuation of inflammation and oxidative stress without interfering with doxorubicin efficacy. Neurotherapeutics 18(3):2107\u20132125","journal-title":"Neurotherapeutics"},{"key":"628_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfca.2024.107141","volume":"139","author":"L Wei","year":"2025","unstructured":"Wei L, Wang H, Wu J, Mao J, Wang S, Qiu J (2025) Ultra-sensitive label-free biosensor for doxorubicin detection by doxorubicin optimized aptamer. J Food Compos Anal 139:107141","journal-title":"J Food Compos Anal"},{"key":"628_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.679610","volume":"12","author":"J Chen","year":"2021","unstructured":"Chen J, Qian C, Ren P, Yu H, Kong X, Huang C, Luo H, Chen G (2021) Light-responsive micelles loaded with doxorubicin for osteosarcoma suppression. Front Pharmacol 12:679610","journal-title":"Front Pharmacol"},{"issue":"5","key":"628_CR182","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3390\/molecules23051184","volume":"23","author":"R Zilinyi","year":"2018","unstructured":"Zilinyi R, Czompa A, Czegledi A, Gajtko A, Pituk D, Lekli I, Tosaki A (2018) The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: the role of autophagy. Molecules 23(5):1184","journal-title":"Molecules"},{"issue":"24","key":"628_CR183","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1039\/D1TB00551K","volume":"9","author":"Y Qin","year":"2021","unstructured":"Qin Y, Guo T, Wang Z, Zhao Y (2021) The role of iron in doxorubicin-induced cardiotoxicity: recent advances and implication for drug delivery. J Mater Chem B 9(24):4793\u20134803","journal-title":"J Mater Chem B"},{"issue":"2","key":"628_CR184","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Prasad SV, Mutharasan RK, Naik TJ, Ardehali H (2014) Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig 124(2):617\u2013630","journal-title":"J Clin Investig"},{"issue":"13","key":"628_CR185","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","volume":"111","author":"PW Fisher","year":"2005","unstructured":"Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111(13):1601\u20131610","journal-title":"Circulation"},{"issue":"5","key":"628_CR186","first-page":"173","volume":"2","author":"S Koka","year":"2010","unstructured":"Koka S, Kukreja RC (2010) Attenuation of doxorubicin-induced cardiotoxicity by tadalafil: a long acting phosphodiesterase-5 inhibitor. Mol Cell Pharmacol 2(5):173","journal-title":"Mol Cell Pharmacol"},{"key":"628_CR187","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11010-020-03779-7","volume":"471","author":"A Samidurai","year":"2020","unstructured":"Samidurai A, Xi L, Salloum FN, Das A, Kukreja RC (2020) PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice. Mol Cell Biochem 471:189\u2013201","journal-title":"Mol Cell Biochem"},{"key":"628_CR188","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40959-018-0027-0","volume":"4","author":"A Poklepovic","year":"2018","unstructured":"Poklepovic A, Qu Y, Dickinson M, Kontos MC, Kmieciak M, Schultz E, Bandopadhyay D, Deng X, Kukreja RC (2018) Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. Cardio-Oncol 4:1\u201311","journal-title":"Cardio-Oncol"},{"issue":"47","key":"628_CR189","doi-asserted-by":"publisher","first-page":"14010","DOI":"10.1021\/bi026182m","volume":"41","author":"SK Chatterjee","year":"2002","unstructured":"Chatterjee SK, Laffray J, Patel P, Ravindra R, Qin Y, Kuehne ME, Bane SL (2002) Interaction of tubulin with a new fluorescent analogue of vinblastine. Biochemistry 41(47):14010\u201314018","journal-title":"Biochemistry"},{"issue":"1","key":"628_CR190","doi-asserted-by":"publisher","first-page":"1883222","DOI":"10.1080\/23311975.2021.1883222","volume":"8","author":"BAA Ghaleb","year":"2021","unstructured":"Ghaleb BAA, Qaderi SA, Almashaqbeh A, Qasem A (2021) Corporate social responsibility, board gender diversity and real earnings management: the case of Jordan. Cogent Bus Manag 8(1):1883222","journal-title":"Cogent Bus Manag"},{"issue":"14","key":"628_CR191","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.3390\/ijms22147439","volume":"22","author":"KJ Lee","year":"2021","unstructured":"Lee KJ, Wright G, Bryant H, Wiggins LA, Dal Zotto VL, Schuler M, Malozzi C, Cohen MV, Gassman NR (2021) Cytoprotective effect of vitamin D on doxorubicin-induced cardiac toxicity in triple negative breast cancer. Int J Mol Sci 22(14):7439","journal-title":"Int J Mol Sci"},{"issue":"9","key":"628_CR192","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.bcp.2013.07.005","volume":"86","author":"LA Ahmed","year":"2013","unstructured":"Ahmed LA, El-Maraghy SA (2013) Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection. Biochem Pharmacol 86(9):1301\u20131310","journal-title":"Biochem Pharmacol"},{"key":"628_CR193","doi-asserted-by":"publisher","first-page":"670479","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG (2021) Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician. Front Pharmacol 12:670479","journal-title":"Front Pharmacol"},{"issue":"3","key":"628_CR194","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/pharmaceutics15030785","volume":"15","author":"T Attachaipanich","year":"2023","unstructured":"Attachaipanich T, Chattipakorn SC, Chattipakorn N (2023) Potential roles of melatonin in doxorubicin-induced cardiotoxicity: from cellular mechanisms to clinical application. Pharmaceutics 15(3):785","journal-title":"Pharmaceutics"},{"key":"628_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109895","volume":"117","author":"X Zhang","year":"2023","unstructured":"Zhang X, Gao Y, Yang B, Ma S, Zuo W, Wei J (2023) The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. Int Immunopharmacol 117:109895","journal-title":"Int Immunopharmacol"},{"key":"628_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-019-0853-7","volume":"19","author":"MH Pourhanifeh","year":"2019","unstructured":"Pourhanifeh MH, Sharifi M, Reiter RJ, Davoodabadi A, Asemi Z (2019) Melatonin and non-small cell lung cancer: new insights into signaling pathways. Cancer Cell Int 19:1\u20137","journal-title":"Cancer Cell Int"},{"issue":"1","key":"628_CR197","doi-asserted-by":"publisher","first-page":"25","DOI":"10.21608\/EJH.2017.3694","volume":"40","author":"RI Yassien","year":"2017","unstructured":"Yassien RI, Elsaid AF (2017) The possible protective role of melatonin on doxorubicin induced cardiomyopathy of adult male albino rats. Egypt J Histol 40(1):25\u201336","journal-title":"Egypt J Histol"},{"key":"628_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.06.001","volume":"232","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhu Y, Dong S, Zhang A, Lu Y, Li Y, Lv S, Zhang J (2019) Role of oxidative stress in cardiotoxicity of antineoplastic drugs. Life Sci 232:116526","journal-title":"Life Sci"},{"key":"628_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2023.153597","volume":"494","author":"C Zhuo","year":"2023","unstructured":"Zhuo C, Xin J, Huang W, Zhang D, Yan X, Li R, Li H, Lan J, Lin L, Li L, Wang X (2023) Irisin protects against doxorubicin-induced cardiotoxicity by improving AMPK-Nrf2 dependent mitochondrial fusion and strengthening endogenous anti-oxidant defense mechanisms. Toxicology 494:153597","journal-title":"Toxicology"},{"key":"628_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.872057","volume":"13","author":"X Hu","year":"2022","unstructured":"Hu X, Li C, Wang Q, Wei Z, Chen T, Wang Y, Li Y (2022) Dimethyl fumarate ameliorates doxorubicin-induced cardiotoxicity by activating the Nrf2 pathway. Front Pharmacol 13:872057","journal-title":"Front Pharmacol"},{"issue":"4","key":"628_CR201","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1159\/000512848","volume":"146","author":"H Lin","year":"2021","unstructured":"Lin H, Liang G, Wu Y, Chen L (2021) Protective effects of ACEI\/ARB on left ventricular function in anthracycline-induced chronic cardiotoxicity: a meta-analysis of randomized controlled trials. Cardiology 146(4):469\u2013480","journal-title":"Cardiology"},{"issue":"1","key":"628_CR202","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/CIRCULATIONAHA.108.799700","volume":"119","author":"W Zhu","year":"2009","unstructured":"Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 119(1):99\u2013106","journal-title":"Circulation"},{"key":"628_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.616505","volume":"12","author":"C Chen","year":"2021","unstructured":"Chen C, Chen T, Liang J, Guo X, Xu J, Zheng Y, Guo Z, Chi L, Wei L, Chen X, Ye X (2021) Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS. Front Pharmacol 12:616505","journal-title":"Front Pharmacol"},{"issue":"1","key":"628_CR204","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/cvr\/cvs309","volume":"97","author":"J Ma","year":"2013","unstructured":"Ma J, Wang Y, Zheng D, Wei M, Xu H, Peng T (2013) Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and-independent pathways. Cardiovasc Res 97(1):77\u201387","journal-title":"Cardiovasc Res"},{"issue":"28","key":"628_CR205","doi-asserted-by":"publisher","first-page":"46663","DOI":"10.18632\/oncotarget.16944","volume":"8","author":"N Koleini","year":"2017","unstructured":"Koleini N, Kardami E (2017) Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8(28):46663","journal-title":"Oncotarget"},{"issue":"1","key":"628_CR206","doi-asserted-by":"publisher","first-page":"2019504","DOI":"10.1080\/21688370.2021.2019504","volume":"11","author":"DA Shabaan","year":"2023","unstructured":"Shabaan DA, Mostafa N, El-Desoky MM, Arafat EA (2023) Coenzyme Q10 protects against doxorubicin-induced cardiomyopathy via antioxidant and anti-apoptotic pathway. Tissue Barr 11(1):2019504","journal-title":"Tissue Barr"},{"issue":"2","key":"628_CR207","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.taap.2015.03.029","volume":"285","author":"DJ Conklin","year":"2015","unstructured":"Conklin DJ, Haberzettl P, Jagatheesan G, Baba S, Merchant ML, Prough RA, Williams JD, Prabhu SD, Bhatnagar A (2015) Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 285(2):136\u2013148","journal-title":"Toxicol Appl Pharmacol"},{"issue":"18","key":"628_CR208","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1093\/cvr\/cvac142","volume":"118","author":"TA McKinsey","year":"2022","unstructured":"McKinsey TA, Foo R, Anene-Nzelu CG, Travers JG, Vagnozzi RJ, Weber N, Thum T (2022) Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development. Cardiovasc Res 118(18):3482\u20133498","journal-title":"Cardiovasc Res"},{"issue":"6","key":"628_CR209","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/FJC.0000000000000009","volume":"62","author":"XL Wang","year":"2013","unstructured":"Wang XL, Wang X, Xiong LL, Zhu Y, Chen HL, Chen JX, Wang XX, Li RL, Guo ZY, Li P, Jiang W (2013) Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol 62(6):512\u2013523","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"628_CR210","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1096\/fj.11-197525","volume":"26","author":"L Siggens","year":"2012","unstructured":"Siggens L, Figg N, Bennett M, Foo R (2012) Nutrient deprivation regulates DNA damage repair in cardiomyocytes via loss of the base-excision repair enzyme OGG1. FASEB J: Off Publ Feder Am Soc Exper Biol 26(5):2117","journal-title":"FASEB J: Off Publ Feder Am Soc Exper Biol"},{"issue":"4","key":"628_CR211","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2095-3119(21)63818-2","volume":"21","author":"XX Yan","year":"2022","unstructured":"Yan XX, Liu XY, Hong CUI, Zhao MQ (2022) The roles of microRNAs in regulating root formation and growth in plants. J Integr Agric 21(4):901\u2013916","journal-title":"J Integr Agric"},{"issue":"1","key":"628_CR212","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/toxsci\/kfy012","volume":"163","author":"G Holmgren","year":"2018","unstructured":"Holmgren G, Sartipy P, Andersson CX, Lindahl A, Synnergren J (2018) Expression profiling of human pluripotent stem cell-derived cardiomyocytes exposed to doxorubicin\u2014integration and visualization of multi-omics data. Toxicol Sci 163(1):182\u2013195","journal-title":"Toxicol Sci"},{"issue":"10","key":"628_CR213","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/ehjci\/jeaa144","volume":"22","author":"Y Xu","year":"2021","unstructured":"Xu Y, Lin J, Liang Y, Wan K, Li W, Wang J, Zhu Y, Mui D, Wang L, Li Y, Cheng W (2021) Prognostic value of left ventricular remodelling index in idiopathic dilated cardiomyopathy. European Heart J-Cardiovasc Imag 22(10):1197\u20131207","journal-title":"European Heart J-Cardiovasc Imag"},{"issue":"3","key":"628_CR214","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13556","volume":"21","author":"C Hu","year":"2022","unstructured":"Hu C, Zhang X, Hu M, Teng T, Yuan YP, Song P, Kong CY, Xu SC, Ma ZG, Tang QZ (2022) Fibronectin type III domain-containing 5 improves aging-related cardiac dysfunction in mice. Aging Cell 21(3):e13556","journal-title":"Aging Cell"},{"issue":"4","key":"628_CR215","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41401-020-0473-8","volume":"42","author":"X Zhang","year":"2021","unstructured":"Zhang X, Hu C, Zhang N, Wei WY, Li LL, Wu HM, Ma ZG, Tang QZ (2021) Matrine attenuates pathological cardiac fibrosis via RPS5\/p38 in mice. Acta Pharmacol Sin 42(4):573\u2013584","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"628_CR216","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/cvr\/cvaa141","volume":"117","author":"BS Handa","year":"2021","unstructured":"Handa BS, Li X, Baxan N, Roney CH, Shchendrygina A, Mansfield CA, Jabbour RJ, Pitcher DS, Chowdhury RA, Peters NS, Ng FS (2021) Ventricular fibrillation mechanism and global fibrillatory organization are determined by gap junction coupling and fibrosis pattern. Cardiovasc Res 117(4):1078\u20131090","journal-title":"Cardiovasc Res"},{"issue":"16","key":"628_CR217","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.3390\/jcm13164637","volume":"13","author":"D Erciyes","year":"2024","unstructured":"Erciyes D, Bora ES, Tekindal MA, Erba\u015f O (2024) Demonstration of the protective effect of vinpocetine in diabetic cardiomyopathy. J Clin Med 13(16):4637","journal-title":"J Clin Med"},{"issue":"1","key":"628_CR218","volume":"2015","author":"AC Vandergriff","year":"2015","unstructured":"Vandergriff AC, de Andrade JBM, Tang J, Hensley MT, Piedrahita JA, Caranasos TG, Cheng K (2015) Intravenous cardiac stem cell-derived exosomes ameliorate cardiac dysfunction in doxorubicin induced dilated cardiomyopathy. Stem Cells Int 2015(1):960926","journal-title":"Stem Cells Int"},{"key":"628_CR219","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fphar.2019.00635","volume":"10","author":"AI Abushouk","year":"2019","unstructured":"Abushouk AI, Salem AM, Saad A, Afifi AM, Afify AY, Afify H, Salem HS, Ghanem E, Abdel-Daim MM (2019) Mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy: potential mechanisms, governing factors, and implications of the heart stem cell debate. Front Pharmacol 10:635","journal-title":"Front Pharmacol"},{"key":"628_CR220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-015-0109-y","volume":"6","author":"F Ezquer","year":"2015","unstructured":"Ezquer F, Guti\u00e9rrez J, Ezquer M, Caglevic C, Salgado HC, Calligaris SD (2015) Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears. Stem Cell Res Ther 6:1\u20139","journal-title":"Stem Cell Res Ther"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43044-025-00628-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-025-00628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:29:58Z","timestamp":1741624198000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-025-00628-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":220,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["628"],"URL":"https:\/\/doi.org\/10.1186\/s43044-025-00628-0","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}